Low normal thyroid function attenuates serum alanine aminotransferase elevations in the context of metabolic syndrome and insulin resistance in white people

Clinical Biochemistry

Volumn 47, Issue 12, 2014, Pages 1028-1032

  Dullaart, Robin P F ^a,b   van den Berg, Eline H ^c   van der Klauw, Melanie M ^a,b   Blokzijl, Hans ^c  

^a Department of Endocrinology ^*  (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adiponectin; Alanine aminotransferase; Insulin resistance; Metabolic syndrome; Thyroid stimulating hormone

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; FREE THYROXINE INDEX; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; BLOOD; HOMEOSTASIS; THYROID FUNCTION TEST;

ALANINE TRANSAMINASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; THYROID FUNCTION TESTS;

EID: 84905748948     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.04.016     Document Type: Article

References (46)

1. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
2. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28:339-350.
3. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
4. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
5. Yu A.S., Keeffe E.B. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?. Am J Gastroenterol 2003, 98:955-956.
6. Westerbacka J., Cornér A., Tiikkainen M., Tamminen M., Vehkavaara S., Häkkinen A.M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004, 47:1360-1369.
7. Schindhelm R.K., Dekker J.M., Nijpels G., Bouter L.M., Stehouwer C.D., Heine R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2007, 191:391-396.
8. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35:367-372.
9. Marchesini G., Marzocchi R., Agostini F., Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005, 16:421-427.
10. Byrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012, 29:1098-1107.
11. Adiels M., Taskinen M.R., Packard C., Caslake M.J., Soro-Paavonen A., Westerbacka J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
12. Cachefo A., Boucher P., Vidon C., Dusserre E., Diraison F., Beylot M. Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients. J Clin Endocrinol Metab 2001, 86:5353-5357.
13. Hazlehurst J.M., Tomlinson J.W. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013, 169:R27-R37.
14. Cordeiro A., Souza L.L., Einicker-Lamas M., Pazos-Moura C.C. Non-classic thyroid hormone signalling involved in hepatic lipid metabolism. J Endocrinol 2013, 25(216):R47-R57.
15. Cable E.E., Finn P.D., Stebbins J.W., Hou J., Ito B.R., van Poelje P.D., et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009, 49:407-417.
16. Vatner D.F., Weismann D., Beddow S.A., Kumashiro N., Erion D.M., Liao X.H., et al. Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab 2013, 305:E89-E100.
17. Upadhyay G., Singh R., Kumar A., Kumar S., Kapoor A., Godbole M.M. Severe hyperthyroidism induces mitochondria-mediated apoptosis in rat liver. Hepatology 2004, 39:1120-1130.
18. Pagadala M.R., Zein C.O., Dasarathy S., Yerian L.M., Lopez R., McCullough A.J. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci 2012, 57:528-534.
19. Chung G.E., Kim D., Kim W., Yim J.Y., Park M.J., Kim Y.J., et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012, 57:150-156.
20. Pacifico L., Bonci E., Ferraro F., Andreoli G., Bascetta S., Chiesa C. Hepatic steatosis and thyroid function tests in overweight and obese children. Int J Endocrinol 2013, 2013:381014.
21. Targher G., Montagnana M., Salvagno G., Moghetti P., Zoppini G., Muggeo M., et al. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clin Endocrinol (Oxf) 2008, 68:481-484.
22. Walsh J.P. Setpoints and susceptibility: do small differences in thyroid function really matter?. Clin Endocrinol (Oxf) 2011, 75:158-159.
23. Asvold B.O., Bjøro T., Nilsen T.I., Gunnell D., Vatten L.J. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med 2008, 168:855-860.
24. Dullaart R.P.F., de Vries R., Roozendaal C., Kobold A.C., Sluiter W.J. Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjects. Clin Endocrinol (Oxf) 2007, 67:668-673.
25. Triolo M., Kwakernaak A.J., Perton F.G., de Vries R., Dallinga-Thie G.M., Dullaart R.P.F. Low normal thyroid function enhances plasma cholesteryl ester transfer in Type 2 diabetes mellitus. Atherosclerosis 2013, 228:466-471.
26. Triolo M., de Boer J.F., Annema W., Kwakernaak A.J., Tietge U.J., Dullaart R.P.F. Low normal free T4 confers decreased high-density lipoprotein antioxidative functionality in the context of hyperglycaemia. Clin Endocrinol (Oxf) 2013, 79:416-423.
27. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
28. Dullaart R.P.F., de Vries R., van Tol A., Sluiter W.J. Lower plasma adiponectin is a marker of increased intima-media thickness associated with Type 2 diabetes mellitus and with male gender. Eur J Endocrinol 2007, 156:387-394.
29. Selvin S. Statistical analysis of epidemiological data 1996, Oxford University Press, New York.
30. Lu M., Lyden P.D., Brott T.G., Hamilton S., Broderick J.P., Grotta J.C. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods 2005, 143:209-216.
31. Kawano Y., Cohen D.E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013, 48:434-441.
32. Kotronen A., Juurinen L., Hakkarainen A., Westerbacka J., Cornér A., Bergholm R., et al. Liver fat is increased in Type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008, 31:165-169.
33. Roos A., Bakker S.J., Links T.P., Gans R.O.B., Wolffenbuttel B.H.R. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007, 92:491-496.
34. Garduño-Garcia J.de J., Alvirde-Garcia U., López-Carrasco G., Padilla Mendoza M.E., Mehta R., Arellano-Campos O., et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol 2010, 163:273-278.
35. Eshraghian A., Dabbaghmanesh M.H., Eshraghian H., Fattahi M.R., Omrani G.R. Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors. Arch Iran Med 2013, 16:584-589.
36. Xu C., Xu L., Yu C., Miao M., Li Y. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf) 2011, 75:240-246.
37. Finelli C., Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?. World J Gastroenterol 2013, 19:802-812.
38. Turer A.T., Browning J.D., Ayers C.R., Das S.R., Khera A., Vega G.L., et al. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart study. J Clin Endocrinol Metab 2012, 97:E982-E986.
39. Mourouzis I., Giagourta I., Galanopoulos G., Mantzouratou P., Kostakou E., Kokkinos A.D., et al. Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: a response associated with up-regulation of Akt/mTOR and AMPK activation. Metabolism 2013, 62:1387-1393.
40. Hara T., Namba H., Takamura N., Yang T.T., Nagayama Y., Fukata S., et al. Thyrotropin regulates c-Jun N-terminal kinase (JNK) activity through two distinct signal pathways in human thyroid cells. Endocrinology 1999, 140:1724-1730.
41. Tae W.J., Yong J.L., Myung W.L., Seon M.K., Tae W.J. Full-length adiponectin protects hepatocytes from palmitate-induced apoptosis via inhibition of c-Jun NH2 terminal kinase. FEBS J 2009, 276:2278-2284.
42. Tarantino G1., Scopacasa F., Colao A., Capone D., Tarantino M., Grimaldi E., et al. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. World J Gastroenterol 2011, 17:5280-5288.
43. Tarantino G., Caputi A. JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011, 17:3785-3794.
44. Tarantino G., Colao A., Capone D., Conca P., Tarantino M., Grimaldi E., et al. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J Biol Regul Homeost Agents 2011, 25:47-56.
45. Riemens S.C., Sluiter W.J., Dullaart R.P.F. Enhanced escape of non-esterified fatty acids from tissue uptake: its role in impaired insulin-induced lowering of total rate of appearance in obesity and Type II diabetes mellitus. Diabetologia 2000, 43:416-426.
46. Messarah M., Boumendjel A., Chouabia A., Klibet F., Abdennour C., Boulakoud M.S., et al. Influence of thyroid dysfunction on liver lipid peroxidation and antioxidant status in experimental rats. Exp Toxicol Pathol 2010, 62:301-310.